A Phase 1 Safety Study of LY2787106 in Patients With Cancer and Anemia

Status
Active
Cancer Type
Non-Hodgkin Lymphoma
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01340976
Protocol IDs
13131 (primary)
I3S-MC-JABA
Study Sponsor
Eli Lilly and Company

Summary

This study will evaluate the safety LY2787106 in patients with cancer and anemia. It will also evaluate when LY2787106 can improve anemia. This study has two parts: Part A is a dose escalation evaluation. Part B is a randomized, double-blinded evaluation of LY2787106 at 2 different dose levels.